LLY:NYSEEli Lilly and Company analysis

Eli Lilly delivered a blockbuster Q1 2026, with revenue soaring 55.5% YoY to $19.8 bn and non‑GAAP EPS beating consensus by 25.9%. The earnings beat, combined with a bullish technical setup—price trading above the 20‑, 50‑ and 200‑day SMAs, a MACD histogram in positive territory and an RSI of 68—has propelled the stock to $1,065, just shy of the $1,070 resistance while comfortably above the $850 support. Volume is tapering, yet market sentiment is at “Extreme Greed” (91.6 on the Fear‑Greed Index), underscoring strong investor enthusiasm despite a 30‑day volatility of over 40% and a max drawdown of ~23%.
Valuation metrics tell a more cautious story: a trailing P/E of ~38 far exceeds the industry average of 27.6, and the discounted‑cash‑flow model pins a fair value near $322, implying the stock is markedly overvalued at current levels. Nonetheless, the dividend appears sustainable with a 0.65% yield and a modest 22% payout ratio backed by robust cash flow. Considering a low beta (~0.58), moderate overall risk, and a pipeline rich in obesity, diabetes and oncology assets, the consensus remains a “Buy” with a medium‑term hold stance and a strong long‑term upside case.